FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.
FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral (ARV) agents.
The recommended oral dose of etravirine tablets is 200 mg (one 200-mg tablet or two 100-mg tablets) taken twice a day following a meal. The new 200-mg product formulation is expected to launch in the United States sometime this month. The 100-mg tablet will remain available.
Patients who are unable to swallow etravirine tablets whole may disperse the tablets in a glass of water.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.